News

NIH office to phase out HIV guidelines by next year
The National Institutes of Health office responsible for issuing federal guidelines related to treatment of HIV and AIDS ...
U.S. approves first-ever biannual shot to prevent HIV, but getting it might be hard
WASHINGTON — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global ...
Should You Buy Gilead Stock At $110?
Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performance this year, with its stock up 18% compared to the S&P ...
The world’s only twice-a-year shot to prevent HIV could stop transmission — if people can get it
The Food and Drug Administration has approved the world’s only twice-a-year shot to prevent HIV. In two groundbreaking ...
US FDA approves Gilead's twice-yearly injection for HIV prevention
The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences lenacapavir, a twice-yearly injection, for ...
Agence France-Presse on MSN3d
US approves Gilead's twice-yearly injection to prevent HIV
The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV -- a move ...
FDA Approves Gilead’s HIV Shot. It Works 99.9% of the Time.
The Food and Drug Administration approved a twice-yearly shot that prevented HIV infections in 99.9% of the people who ...
The Malaysian Reserve3h
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. – GILD
Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. ("Gilead" or the "Company") ...
Fierce Pharma3d
FDA signs off on Gilead's landmark long-acting PrEP med, signaling new era in HIV prevention
With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo ...
STAT3d
Gilead’s CEO on the approval of a powerful new drug to prevent HIV
Gilead's CEO says he's committed to making sure people around the world can get his firm's new HIV prevention shot Yeztugo.
pharmaphorum3d
Gilead's twice-yearly PrEP drug is cleared by FDA
Gilead is now waiting for regulatory decisions on the twice-yearly PrEP in Europe and other markets, including South Africa ...